| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits the proteasome, disrupting antigen processing and MHC class I presentation by degrading proteins. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Similar to Bortezomib, MG132 also inhibits proteasome activity to affect antigen presentation. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Another proteasome inhibitor that impairs MHC class I presentation by disrupting protein degradation. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Binds to and inhibits the proteasome, leading to a reduction in MHC class I antigen presentation. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
A proteasome inhibitor that interferes with protein degradation, affecting MHC class I pathway. | ||||||
NLG919 | 1402836-58-1 | sc-478118 | 10 mg | $352.00 | ||
Inhibits the enzyme IDO1, reducing tryptophan catabolism and promoting better MHC class I responses. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Modulates thioredoxin reductase, influencing MHC class I presentation by altering redox status. | ||||||
2-Methoxyestradiol | 362-07-2 | sc-201371 sc-201371A | 10 mg 50 mg | $71.00 $288.00 | 6 | |
Disrupts microtubule dynamics, affecting antigen trafficking and MHC class I presentation. | ||||||
6-Formylindolo[3,2-b]carbazole | 172922-91-7 | sc-300019A sc-300019 | 100 µg 5 mg | $105.00 $2185.00 | 5 | |
Binds to and activates the aryl hydrocarbon receptor (AhR), influencing MHC class I pathways. | ||||||
Leflunomide | 75706-12-6 | sc-202209 sc-202209A | 10 mg 50 mg | $20.00 $83.00 | 5 | |
Interferes with de novo pyrimidine synthesis, indirectly affecting MHC class I presentation. | ||||||